Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib scheduling with weekly paclitaxel in metastatic uveal melanoma
ISRCTN29621851Phase 2Completed
- Sponsor
- University of Liverpool
- Start
- Aug 2015
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of selumetinib and paclitaxel in intraocular melanoma (2 arms), sponsored by University of Liverpool. Primary endpoint: Progression-free survival. Started Aug 2015; status: completed.
02
Drugs
selumetinibpaclitaxel
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on ISRCTN29621851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN29621851.